TCGA-85-8353-01A-21R-2296-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 72
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.610
- HEDGEHOG_SIGNALING+0.540
- WNT_BETA_CATENIN_SIGNALING+0.500
- HYPOXIA+0.490
- ANGIOGENESIS+0.480
- TNFA_SIGNALING_VIA_NFKB+0.470
- MITOTIC_SPINDLE+0.430
- TGF_BETA_SIGNALING+0.420
- IL2_STAT5_SIGNALING+0.390
- UV_RESPONSE_DN+0.390
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.420
- INTERFERON_ALPHA_RESPONSE-0.340
- PEROXISOME-0.270
- ADIPOGENESIS-0.260
- FATTY_ACID_METABOLISM-0.230
- PANCREAS_BETA_CELLS-0.230
- BILE_ACID_METABOLISM-0.190
- SPERMATOGENESIS-0.150
- XENOBIOTIC_METABOLISM-0.100
- DNA_REPAIR-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-8582-01A-21R-2403-07 | — | cohortSQ1 | 0.880 |
| 2 | TCGA-56-6545-01A-11R-1820-07 | — | cohortSQ1 | 0.847 |
| 3 | DRR168559 | — | — | 0.838 |
| 4 | TCGA-22-4609-01A-21R-2125-07 | — | cohortSQ1 | 0.837 |
| 5 | TCGA-CV-6959-01A-11R-1915-07 | — | — | 0.832 |
| 6 | TCGA-BH-A1FU-01A-11R-A14D-07 | — | C | 0.831 |
| 7 | SRR33346953 | — | — | 0.831 |
| 8 | SJEPD032038_D1.RNA-Seq | EPN | Supratentorial EPN | 0.830 |
| 9 | b9cadac9-9bb4-4bc8-9303-d05ad06778cc | — | — | 0.830 |
| 10 | TCGA-77-8138-01A-11R-2247-07 | — | cohortSQ1 | 0.829 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.610 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.540 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.500 | Inavolisib | — uncovered |
| HYPOXIA | 0.490 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.480 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.470 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.430 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.420 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.390 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.370 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.350 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.350 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.340 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| APOPTOSIS | 0.330 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |